Cicaliquid ldh j

To evaluate adverse effects of high dose probucol we measured 13 biomarkers using blood samples. Erythrocyte-, leukocyte-, and platelet-counts in blood samples were measured by using an automatic blood cell counter (Celltac α MEK-6458, Nihon Kohden, Tokyo, Japan). Blood aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), blood urea nitrogen, and their corresponding levels in serum were determined using CicaLiquid AST, CicaLiquid ALT, CicaLiquid LDH J, CicaLiquid-N UN (Kanto Chemical Co., Inc., Tokyo, Japan), respectively. Serum creatinine levels were determined using Determiner L CRE (Kyowa Medex Co., Ltd., Tokyo, Japan). Total protein levels in serum were determined using Clinimate TP (Sekisui Medical Co., Ltd., Tokyo, Japan). Serum concentrations of sodium, potassium and chloride were measured using Bio Majesty JCA-BM8060 (JEOL, Tokyo, Japan). Plasma cortisol levels were measured using electrochemiluminescence immunoassay (ECLIA, Roche Diagnostics, Mannheim, Germany).
Urine samples were analyzed for leukocyte, urobilinogen, occult blood reaction, bilirubin, ketonic metabolite, glucose, protein and pH values by using dipstick urinalysis (Uropaper III, Eiken Chemical Co., Ltd., Tokyo).

The levels of Krebs von den Lungen-6 (KL-6) (Picolumi KL-6; EIDIA, Tokyo, Japan), SP-D (SP-D kit YAMASA EIA II; Kyowa Medex, Chiba, Japan), SP-A (SP-A test Kokusai-F kit; SYSMEX, Kobe, Japan), and lactate dehydrogenase (LDH) (Cica Liquid LDH J; Kanto Chemical, Tokyo, Japan) in the serum were measured. The reference levels of normal human serum in this study were KL-6 (< 500 U/mL), SP-D (< 110 ng/mL), SP-A (< 48.3 ng/mL), and LDH (115 < LDH < 229 IU/L).
We measured the levels of anti-GM-CSF autoantibody in the serum using a specific previously reported ELISA method [1 (link), 23 (link), 24 (link)] with partial modification.